<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140005109A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140005109</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13979451</doc-number><date>20120113</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>505</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>505</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc></classifications-cpc><classification-national><country>US</country><main-classification>514  77</main-classification><further-classification>530380</further-classification><further-classification>536 235</further-classification><further-classification>514 44  R</further-classification><further-classification>4353201</further-classification><further-classification>4352523</further-classification><further-classification>435348</further-classification><further-classification>43525411</further-classification><further-classification>4352542</further-classification><further-classification>435419</further-classification><further-classification>435325</further-classification><further-classification>435366</further-classification><further-classification>43525233</further-classification><further-classification>43525231</further-classification><further-classification>43525421</further-classification><further-classification>435369</further-classification><further-classification>4352544</further-classification><further-classification>435363</further-classification><further-classification>435367</further-classification><further-classification>435360</further-classification><further-classification>435352</further-classification><further-classification>4353651</further-classification></classification-national><invention-title id="d0e43">Therapeutic Compositions and Methods for Disorders Associated with Neuronal Degeneration</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>61433186</doc-number><date>20110114</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>61441512</doc-number><date>20110210</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only"><addressbook><last-name>Rex</last-name><first-name>Tonia S.</first-name><address><city>Goodlettsville</city><state>TN</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="01" app-type="applicant" designation="us-only"><addressbook><last-name>Sullivan</last-name><first-name>Timothy A.</first-name><address><city>Savannah</city><state>GA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Rex</last-name><first-name>Tonia S.</first-name><address><city>Goodlettsville</city><state>TN</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Sullivan</last-name><first-name>Timothy A.</first-name><address><city>Savannah</city><state>GA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION</orgname><role>02</role><address><city>Memphis</city><state>TN</state><country>US</country></address></addressbook></assignee></assignees><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/US12/21247</doc-number><kind>00</kind><date>20120113</date></document-id><us-371c124-date><date>20130919</date></us-371c124-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Disclosed are isolated mutant erythropoietin (EPO) polypeptides, functional fragment thereof, nucleic acid encoding such peptides, vectors including such nucleic acids and compositions including such peptides and nucleic acids. The mutant EPO peptides are unique in that they include a substitution at amino acid position number 76, such as a glutamic acid for arginine substitution at position 76. This substitution inhibits erythropoietic activity while retaining their neuroprotection. Also disclosed are methods of treating or inhibiting neuronal degeneration, reducing or inhibiting one or more symptoms associated with neuronal degeneration and/or glaucoma in a subject. The methods include administering a therapeutically effective amount of a isolated mutant erythropoietin EPO polypeptide, an expression vector encoding such a mutant erythropoietin EPO polypeptide, a viral particle including an expression vector, or a composition, thereby treating or inhibiting neuronal degeneration in the subject.</p></abstract></us-patent-application>